The clinical momentum in both Alzheimer's and Parkinson's programs provides potential upside, but the narrow cash runway into Q3 2026 suggests a near-term financing need, which could lead to further dilution. Traders should monitor enrollment progress in the Phase 3 AD trial and any updates on the planned PDD study design with the FDA.
Price Chart
Executive Summary
Annovis Bio reported financial results for 2025 alongside clinical progress updates, including initiation of a pivotal Phase 3 trial in Alzheimer's disease and an open-label extension study in Parkinson's disease. The company showed improved net loss per share despite higher R&D spending, with cash of $19.5 million enabling operations into Q3 2026.
Key Financial Metrics
Key Facts
- Initiated pivotal Phase 3 trial in early Alzheimer's disease (NCT06709014) with 65% enrollment achieved by March 2026 across 83 U.S. sites.
- Launched open-label extension (OLE) study in Parkinson's disease (NCT07284784) in January 2026 to assess long-term safety and efficacy over 36 months.
- Received positive DSMB safety review for buntanetap at 6 months in the AD trial, supporting continuation without modifications.
- Met with FDA in January 2026 to discuss a potential Phase 3 trial in Parkinson's disease dementia (PDD), receiving a positive recommendation to proceed.
- Transferred patents to a new crystal form of buntanetap with improved stability, extending IP protection until 2047; 40 granted patents and 48 applications held as of year-end 2025.
- R&D expenses increased to $25.2M in 2025 from $20.0M in 2024, while G&A decreased to $4.5M from $6.7M.
- Net loss per share improved to $1.40 (basic and diluted) in 2025 vs. $2.02 (basic) and $2.31 (diluted) in 2024, despite larger total net loss due to share count increase.
- Cash and cash equivalents rose to $19.5M as of December 31, 2025, up from $10.6M in 2024; funding expected to last into Q3 2026.
Financial Impact
Net loss widened to $28.85M in 2025 from $24.59M in 2024, but per-share losses decreased due to dilution from share count rising to 27.2M. Cash position increased by $8.98M, likely from equity offerings.
Risk Factors
- Limited cash runway extending only into Q3 2026, increasing risk of near-term dilutive financing.
- No revenue-generating products; valuation dependent entirely on clinical trial outcomes.
- High market cap relative to cash and stage of development increases volatility risk if trial data disappoints.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256164 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 10, 2026 12w ago | 8-K | $1.86 $1.88 | ▲ +1.08% | ▼ −1.35% | $1.18 (−36.56%) |
May 20, 2026 19w ago | 424B5 | $2.15 $1.73 | ▲ +19.53% | ▲ +19.87% | $1.18 (+45.12%) |
May 19, 2026 19w ago | 424B5 | $2.04 $1.75 | ▲ +14.22% | ▲ +14.96% | $1.18 (+42.16%) |
May 15, 2026 20w ago | 8-K | $2.05 $1.79 | ▼ −12.68% | ▼ −14.26% | $1.18 (−42.44%) |
May 15, 2026 20w ago | Press Release | $2.06 $1.78 | ▲ +13.59% | ▲ +15.71% | $1.18 (+42.72%) |
Apr 10, 2026 25w ago | Press Release | $1.59 $2.26 | ▲ +42.14% | ▲ +33.61% | $1.18 (−25.79%) |
Mar 19, 2026 28w ago | Press Release | $2.67 $1.87 | ▼ −29.96% | ▼ −37.58% | $1.18 (−55.81%) |
Mar 16, 2026 28w ago | Press Release | $2.83 $1.73 | ▼ −38.87% | ▼ −42.65% | $1.18 (−58.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access